JP2018518540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518540A5 JP2018518540A5 JP2018519261A JP2018519261A JP2018518540A5 JP 2018518540 A5 JP2018518540 A5 JP 2018518540A5 JP 2018519261 A JP2018519261 A JP 2018519261A JP 2018519261 A JP2018519261 A JP 2018519261A JP 2018518540 A5 JP2018518540 A5 JP 2018518540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- binding protein
- antigen
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117516A JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183297P | 2015-06-23 | 2015-06-23 | |
| US62/183,297 | 2015-06-23 | ||
| US201562266398P | 2015-12-11 | 2015-12-11 | |
| US62/266,398 | 2015-12-11 | ||
| PCT/US2016/039015 WO2016210129A1 (en) | 2015-06-23 | 2016-06-23 | Novel pd-1 immune modulating agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117516A Division JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518540A JP2018518540A (ja) | 2018-07-12 |
| JP2018518540A5 true JP2018518540A5 (enExample) | 2019-08-08 |
| JP6974311B2 JP6974311B2 (ja) | 2021-12-01 |
Family
ID=56373127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519261A Active JP6974311B2 (ja) | 2015-06-23 | 2016-06-23 | 新規ｐｄ−１免疫調節剤 |
| JP2021117516A Ceased JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117516A Ceased JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11136392B2 (enExample) |
| EP (1) | EP3313883B1 (enExample) |
| JP (2) | JP6974311B2 (enExample) |
| KR (1) | KR20180019725A (enExample) |
| CN (2) | CN108337890B (enExample) |
| AU (1) | AU2016281641B2 (enExample) |
| CA (1) | CA3006224A1 (enExample) |
| HK (1) | HK1254803A1 (enExample) |
| IL (1) | IL256463A (enExample) |
| TW (1) | TWI773647B (enExample) |
| WO (1) | WO2016210129A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3298033T (pt) | 2015-05-18 | 2020-09-22 | Tcr2 Therapeutics Inc | Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão |
| CA3006224A1 (en) * | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Novel pd-1 immune modulating agents |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| CA2993432A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| US10428145B2 (en) | 2015-09-29 | 2019-10-01 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
| PT3356411T (pt) | 2015-10-02 | 2021-08-30 | Hoffmann La Roche | Anticorpos biespecíficos específicos para pd1 e tim3 |
| RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| WO2017165683A1 (en) * | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| WO2018117069A1 (ja) * | 2016-12-19 | 2018-06-28 | 昭和電工株式会社 | レドックスフロー電池の運転方法 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| DK3606946T3 (da) | 2017-04-03 | 2022-10-24 | Hoffmann La Roche | Immunkonjugater af et anti-PD-1-antistof med et muteret IL-2 eller med IL-15 |
| SI3606955T1 (sl) | 2017-04-05 | 2025-03-31 | F. Hoffmann-La Roche Ag | Bispecifična protitelesa, ki specifično vežejo PD1 in LAG3 |
| JP6871415B2 (ja) * | 2017-04-05 | 2021-05-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｌａｇ３抗体 |
| WO2018195348A1 (en) * | 2017-04-19 | 2018-10-25 | University Of Southern California | Compositions and methods for treating cancer |
| WO2018200583A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
| WO2018204303A1 (en) * | 2017-05-01 | 2018-11-08 | The Children's Medical Center Coporation | Methods and compositions relating to anti-pd1 antibody reagents |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| IL271833B2 (en) * | 2017-07-06 | 2024-09-01 | Merus Nv | Antibodies that modulate a biological activity expressed by a cell |
| WO2019018727A1 (en) * | 2017-07-21 | 2019-01-24 | Washington University | METHODS AND COMPOSITIONS FOR T-CELL ACTIVATION |
| DK3703750T3 (da) | 2017-11-01 | 2025-02-10 | Juno Therapeutics Inc | Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20200128014A (ko) * | 2018-01-31 | 2020-11-11 | 셀진 코포레이션 | 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법 |
| EP3752601A4 (en) | 2018-02-15 | 2022-03-23 | Memorial Sloan-Kettering Cancer Center | FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
| EP3818146A4 (en) * | 2018-07-04 | 2022-10-19 | Cytoimmune Therapeutics, Inc. | COMPOSITIONS AND METHODS OF IMMUNOTHERAPY TARGETING FLT3, PD-1 AND/OR PD-L1 |
| CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| CN111320690B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人Tim3单克隆抗体及其应用 |
| CN111748580B (zh) * | 2019-03-28 | 2022-09-13 | 百奥泰生物制药股份有限公司 | 一种检测免疫检查点抗体活性的方法 |
| CN111892655B (zh) * | 2019-05-06 | 2022-10-28 | 四川大学 | 抗pd-1纳米抗体的筛选及应用 |
| CN114679909A (zh) | 2019-05-20 | 2022-06-28 | 潘迪恩运营公司 | MAdCAM靶向的免疫耐受 |
| US20220275088A1 (en) * | 2019-06-14 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| KR20220030956A (ko) | 2019-07-05 | 2022-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료 |
| US12435148B2 (en) | 2019-07-12 | 2025-10-07 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind CXCR4 to modulate cellular function |
| JP7771749B2 (ja) | 2019-08-08 | 2025-11-18 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| US20220289862A1 (en) * | 2019-08-16 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
| CN112852740A (zh) * | 2019-11-27 | 2021-05-28 | 深圳市菲鹏生物治疗股份有限公司 | Car-t细胞和检测方法 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| PE20231076A1 (es) | 2020-05-26 | 2023-07-17 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
| CN114437229B (zh) * | 2020-11-01 | 2024-03-12 | 复旦大学 | 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途 |
| CN112812174A (zh) * | 2021-01-15 | 2021-05-18 | 新乡学院 | 猪pd-l14qn-af表位多肽及其应用 |
| CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
| WO2024182754A2 (en) * | 2023-03-02 | 2024-09-06 | Fred Hutchinson Cancer Center | Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025085538A1 (en) * | 2023-10-17 | 2025-04-24 | Lanier Biotherapeutics, Inc. | Alarmin binding molecules and treatment of cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4834976A (en) * | 1986-07-03 | 1989-05-30 | Genetic Systems Corporation | Monoclonal antibodies to pseudomonas aeruginosa flagella |
| CA2508660C (en) * | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| EP4059964A1 (en) * | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| US8354509B2 (en) * | 2007-06-18 | 2013-01-15 | Msd Oss B.V. | Antibodies to human programmed death receptor PD-1 |
| EP3915588A1 (en) * | 2011-07-29 | 2021-12-01 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN103965363B (zh) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| SG11201704550XA (en) * | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| CN104479020B (zh) * | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
| EP3297673A4 (en) * | 2015-05-22 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES |
| CA3006224A1 (en) * | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Novel pd-1 immune modulating agents |
| NZ743124A (en) * | 2015-12-04 | 2022-11-25 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and methods of use |
| JP7022067B2 (ja) * | 2016-01-14 | 2022-02-17 | メモリアル スローン ケタリング キャンサー センター | Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 |
| CN110392694B (zh) * | 2016-11-02 | 2023-08-04 | 震动疗法股份有限公司 | 针对pd-1的抗体及其用途 |
| CN111433354A (zh) * | 2017-09-26 | 2020-07-17 | 朗沃德大学 | 作为免疫疗法的pd1特异性嵌合抗原受体 |
-
2016
- 2016-06-23 CA CA3006224A patent/CA3006224A1/en not_active Abandoned
- 2016-06-23 TW TW105119709A patent/TWI773647B/zh not_active IP Right Cessation
- 2016-06-23 HK HK18113888.8A patent/HK1254803A1/zh unknown
- 2016-06-23 AU AU2016281641A patent/AU2016281641B2/en active Active
- 2016-06-23 EP EP16736667.3A patent/EP3313883B1/en active Active
- 2016-06-23 CN CN201680037151.1A patent/CN108337890B/zh active Active
- 2016-06-23 CN CN202111160281.3A patent/CN114133448A/zh active Pending
- 2016-06-23 JP JP2018519261A patent/JP6974311B2/ja active Active
- 2016-06-23 KR KR1020187002014A patent/KR20180019725A/ko not_active Withdrawn
- 2016-06-23 WO PCT/US2016/039015 patent/WO2016210129A1/en not_active Ceased
-
2017
- 2017-12-20 US US15/849,107 patent/US11136392B2/en active Active
- 2017-12-20 IL IL256463A patent/IL256463A/en unknown
-
2021
- 2021-07-16 JP JP2021117516A patent/JP2021177768A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518540A5 (enExample) | ||
| HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
| JP2016138129A5 (enExample) | ||
| JP2018035138A5 (enExample) | ||
| JP2018526981A5 (enExample) | ||
| CN113573728A (zh) | 治疗性SIRPα抗体 | |
| JPWO2019129221A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
| HRP20192346T1 (hr) | Molekule anti-lag-3 antitijela i njihove uporabe | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2018527919A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
| JP2013527762A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| JP2013527761A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2018522888A5 (enExample) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2016530223A5 (enExample) |